Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
[en] OBJECTIVES: Patients suffering from invasive mycoses often receive concomitant antifungal therapy and antibacterial agents. Ciprofloxacin, a carboxyfluoroquinolone, was previously observed to demonstrate the pharmacodynamic interactions with antifungal agents by altering their growth inhibitory activity against Candida albicans and Aspergillus fumigatus. However, little is known about the interaction between other extended-spectrum fluoroquinolones, such as levofloxacin and moxifloxacin, and antifungal agents against C. albicans and A. fumigatus. METHODS: Using a microdilution chequerboard technique, we employed isobolographic analysis adapted to incorporate a non-active agent in order to analyse the potential in vitro interaction between ciprofloxacin, levofloxacin or moxifloxacin and the following representative antifungal agents: amphotericin B, fluconazole or voriconazole and caspofungin. RESULTS: Synergistic interactions [interaction indices (Iis) 0.69-0.83, P < 0.05] were observed between amphotericin B (0.07-0.31 mg/L) and either ciprofloxacin (0.19-7.65 mg/L) or levofloxacin (0.41-32.88 mg/L) against C. albicans and A. fumigatus. Synergy (Iis 0.56-0.87, P < 0.05) also was found between voriconazole (0.09-0.14 mg/L) and ciprofloxacin (0.22-11.41 mg/L) as well as between caspofungin (8.94-22.07 mg/L) and levofloxacin (0.14-5.17 mg/L) against A. fumigatus. Some antagonistic (Iis 1.16-1.29, P < 0.05) interactions were observed between fluoroquinolones and fluconazole against C. albicans. In general, ciprofloxacin enhanced the activity of antifungal agents more than moxifloxacin and levofloxacin against both C. albicans and A. fumigatus. CONCLUSIONS: The knowledge of the pharmacodynamic interactions between fluoroquinolones and antifungal agents may guide selection and potentially improve the outcome of immunosuppressed patients with concurrent bacterial and fungal infections.
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
Agusti C, Rano A, Sibila O et al. Nosocomial pneumonia in immunosuppressed patients. Infect Dis Clin North Am 2003; 17 785-800.
Pascoe J, Cullen M. The prevention of febrile neutropenia. Curr Opin Oncol 2006; 18: 325-9.
Van Bambeke F, Michot JM, Van Eldere J et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-80.
Stergiopoulou T, Meletiadis J, Sein T et al. Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother 2008; 52: 2196-204.
Sugar AM, Liu XP, Chen RJ. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother 1997; 41: 2518-21.
Sasaki E, Maesaki S, Miyazaki Y et al. Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. J Infect Chemother 2000; 6: 151-4.
Nakajima R, Kitamura A, Someya K et al. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 1995; 39: 1517-21.
Wagenlehner FM, Kees F, Weidner W et al. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents 2008; 31: 21-6.
Wagenlehner FM, Kinzig-Schippers M, Sorgel F et al. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 2006; 28: 551-9.
Shen LL, Baranowski J, Fostel J et al. DNA topoisomerases from pathogenic fungi: Targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 1992; 36: 2778-84.
Michot JM, Seral C, Van Bambeke F et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 2005; 49: 2429-37.
Garrison MW, Anderson DE, Campbell DM et al. Stenotrophomonas maltophilia: Emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996; 40: 2859-64.
Sternal K, Czub J, Baginski M. Molecular aspects of the interaction between amphotericin B and a phospholipid bilayer: Molecular dynamics studies. J Mol Model 2004; 10: 223-32.
Robertson SM, Curtis MA, Schlech BA et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005; 50 Suppl 1: S32-45.
Petrou MA, Rogers TR. In-vitro activity of antifungal agents in combination with four quinolones. Drugs Exp Clin Res 1988; 14 9-18.
Michot JM, Van Bambeke F, Mingeot-Leclercq MP et al. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob Agents Chemother 2004; 48: 2673-82.
Park S, Perlin DS. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist 2005; 11: 232-8.
Shalit I, Halperin D, Haite D et al. Anti-inflammatory effects of moxifloxacin on IL-8, IL-1β and TNF-α secretion and NFκB and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemother 2006; 57: 230-5.
Shalit I, Horev-Azaria L, Fabian I et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 2002; 46: 2442-9.
